Literature DB >> 9472674

Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: cholera toxin induces a Th1-like response to Bet v 1, the major birch pollen allergen.

U Wiedermann1, B Jahn-Schmid, R Fritsch, L Bauer, H Renz, D Kraft, C Ebner.   

Abstract

Based on the fact that type I allergies are frequently elicited by inhalant allergens, we have established a model of aerosol inhalation leading to allergic sensitization in BALB/c mice. Using this model we studied the effects of aluminium hydroxide (Al(OH)3), known to enhance IgE antibody responses, compared with cholera toxin (CT), a potent mucosal adjuvant, on the immune response to birch pollen (BP) and its major allergen Bet v 1. Two groups of BALB/c mice were either systemically immunized with recombinant Bet v 1 in Al(OH)3 and subsequently aerosol exposed to BP allergen, or aerosolized with BP and CT. IgE-mediated skin reactions were only elicited in the mice which had received Bet v 1/Al(OH)3. Allergen-specific serum IgE and IgG1 antibodies dominated in the Al(OH)3 group, IgG2a antibody levels to BP and rBet v 1 were markedly higher in the sera of mice exposed to CT with the allergen. IgA antibodies were only detected in the bronchial lavage of the CT-treated group. Moreover, the latter group displayed consistently higher T cell proliferative responses to BP and interferon-gamma production in vitro. Thus, the systemic immunization with rBet v 1 in Al(OH)3 before inhalation of the BP extract promoted a Th2-like immune response, while CT mixed with the aerosolized BP extract rather induced a Th1-like immune response. In an attempt to reverse these ongoing immune responses we could achieve a shift towards a Th0 response. Immunization with BP extract without adjuvant treatment led to undetectable antibody or cellular immune responses. We conclude from the present study that the induction of an immune response to BP allergen after aerosol inhalation can be directed towards a Th1- or a Th2-like response. Once established, the immune response can be modulated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9472674      PMCID: PMC1904846          DOI: 10.1046/j.1365-2249.1998.00477.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  53 in total

1.  The in vitro production of cytokines by mucosal lymphocytes immunized by oral administration of keyhole limpet hemocyanin using cholera toxin as an adjuvant.

Authors:  A D Wilson; M Bailey; N A Williams; C R Stokes
Journal:  Eur J Immunol       Date:  1991-10       Impact factor: 5.532

2.  Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4.

Authors:  M Marinaro; H F Staats; T Hiroi; R J Jackson; M Coste; P N Boyaka; N Okahashi; M Yamamoto; H Kiyono; H Bluethmann; K Fujihashi; J R McGhee
Journal:  J Immunol       Date:  1995-11-15       Impact factor: 5.422

Review 3.  Regulation of reaginic antibody formation in animals.

Authors:  T Tada
Journal:  Prog Allergy       Date:  1975

4.  Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures.

Authors:  M Jutel; W J Pichler; D Skrbic; A Urwyler; C Dahinden; U R Müller
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

5.  A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.

Authors:  M Roberts; A Bacon; R Rappuoli; M Pizza; I Cropley; G Douce; G Dougan; M Marinaro; J McGhee; S Chatfield
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

6.  Interferon-gamma inhibits serotonin release from mouse peritoneal mast cells.

Authors:  J W Coleman; M G Buckley; M R Holliday; A G Morris
Journal:  Eur J Immunol       Date:  1991-10       Impact factor: 5.532

7.  Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss Study on Air Pollution and Lung Diseases in Adults.

Authors:  B Wüthrich; C Schindler; P Leuenberger; U Ackermann-Liebrich
Journal:  Int Arch Allergy Immunol       Date:  1995-02       Impact factor: 2.749

8.  Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin.

Authors:  S Tamura; Y Shoji; K Hasiguchi; C Aizawa; T Kurata
Journal:  Vaccine       Date:  1994-10       Impact factor: 3.641

9.  Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants.

Authors:  G Douce; C Turcotte; I Cropley; M Roberts; M Pizza; M Domenghini; R Rappuoli; G Dougan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

10.  Cellular kinetics of the intestinal immune response to cholera toxoid in rats.

Authors:  N F Pierce; J L Gowans
Journal:  J Exp Med       Date:  1975-12-01       Impact factor: 14.307

View more
  3 in total

1.  Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy.

Authors:  Hans Grönlund; Susanne Vrtala; Ursula Wiedermann; Gerhard Dekan; Dietrich Kraft; Rudolf Valenta; Marianne Van Hage-Hamsten
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy.

Authors:  A Repa; C Wild; K Hufnagl; B Winkler; B Bohle; A Pollak; U Wiedermann
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

3.  Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.

Authors:  G Douce; V Giannelli; M Pizza; D Lewis; P Everest; R Rappuoli; G Dougan
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.